Abstract:Previous studies have shown mitochondrial dysfunction in various acute kidney injuries and chronic kidney diseases. Lipoic acid exerts potent effects on oxidant stress and modulation of mitochondrial function in damaged organ. In this study we investigated whether alpha lipoamide (ALM), a derivative of lipoic acid, exerted a renal protective effect in a type 2 diabetes mellitus mouse model. 9-week-old db/db mice were treated with ALM (50 mg·kg-1·d-1, i.g) for 8 weeks. We showed that ALM administration did not affect blood glucose levels in db/db mice, but restored renal function and significantly improved fibrosis of kidneys. We demonstrated that ALM administration significantly ameliorated mitochondrial dysfunction and tubulointerstitial fibrotic lesions, along with increased expression of CDX2 and CFTR and decreased expression of β-catenin and Snail in kidneys of db/db mice. Similar protective effects were observed in rat renal tubular epithelial cell line NRK-52E cultured in high-glucose medium following treatment with ALM (200 μM). The protective mechanisms of ALM in diabetic kidney disease (DKD) were further explored: Autodock Vina software predicted that ALM could activate RXRα protein by forming stable hydrogen bonds. PROMO Database predicted that RXRα could bind the promoter sequences of CDX2 gene. Knockdown of RXRα expression in NRK-52E cells under normal glucose condition suppressed CDX2 expression and promoted phenotypic changes in renal tubular epithelial cells. However, RXRα overexpression increased CDX2 expression which in turn inhibited high glucose-mediated renal tubular epithelial cell injury. Therefore, we reveal the protective effect of ALM on DKD and its possible potential targets: ALM ameliorates mitochondrial dysfunction and regulates the CDX2/CFTR/β-catenin signaling axis through upregulation and activation of RXRα. Schematic figure illustrating that ALM alleviates diabetic kidney disease by improving mitochondrial function and upregulation and activation of RXRα, which in turn upregulated CDX2 to exert an inhibitory effect on β-catenin activation and nuclear translocation. RTEC renal tubular epithelial cell. ROS Reactive oxygen species. RXRα Retinoid X receptor-α. Mfn1 Mitofusin 1. Drp1 dynamic-related protein 1. MDA malondialdehyde. 4-HNE 4-hydroxynonenal. T-SOD Total-superoxide dismutase. CDX2 Caudal-type homeobox transcription factor 2. CFTR Cystic fibrosis transmembrane conductance regulator. EMT epithelial mesenchymal transition. α-SMA Alpha-smooth muscle actin. ECM extracellular matrix. DKD diabetic kidney disease. Schematic figure was drawn by Figdraw ( www.figdraw.com ).

AKF-PD alleviates diabetic nephropathy via blocking the RAGE/AGEs/NOX and PKC/NOX Pathways

Fluorofenidone attenuates diabetic nephropathy and kidney fibrosis in db/db mice

Polydatin Promotes Nrf2-ARE Anti-Oxidative Pathway Through Activating CKIP-1 to Resist HG-induced Up-Regulation of FN and ICAM-1 in GMCs and Diabetic Mice Kidneys.

Polydatin Promotes Nrf2-ARE Anti-Oxidative Pathway Through Activating Sirt1 to Resist AGEs-induced Upregulation of Fibronetin and Transforming Growth Factor-Β1 in Rat Glomerular Messangial Cells.

Polydatin Attenuates AGEs-induced Upregulation of Fibronectin and ICAM-1 in Rat Glomerular Mesangial Cells and Db/db Diabetic Mice Kidneys by Inhibiting the Activation of the SphK1-S1P Signaling Pathway

Fluorofenidone Attenuates Oxidative Stress and Renal Fibrosis in Obstructive Nephropathy Via Blocking NOX2 (gp91phox) Expression and Inhibiting ERK/MAPK Signaling Pathway

EGFR inhibition attenuates diabetic nephropathy through decreasing ROS and endoplasmic reticulum stress.

EGFR Inhibition Attenuates Diabetic Nephropathy Through Decreasing ROS and Endoplasmic Reticulum Stress

Kaempferol attenuated diabetic nephropathy by reducing apoptosis and promoting autophagy through AMPK/mTOR pathways

Protective effect of ginsenoside metabolite compound K against diabetic nephropathy by inhibiting NLRP3 inflammasome activation and NF-κB/p38 signaling pathway in high-fat diet/streptozotocin-induced diabetic mice

Kirenol alleviates diabetic nephropathy via regulating TGF-β/Smads and the NF-κB signal pathway

Andrographolide ameliorates diabetic nephropathy by attenuating hyperglycemia-mediated renal oxidative stress and inflammation via Akt/NF-κB pathway

Fluorofenidone Offers Improved Renoprotection at Early Interventions During the Course of Diabetic Nephropathy in Db/db Mice Via Multiple Pathways.

Alpha lipoamide inhibits diabetic kidney fibrosis via improving mitochondrial function and regulating RXRα expression and activation

CKIP-1 Ameliorates High Glucose-Induced Expression of Fibronectin and Intercellular Cell Adhesion Molecule-1 by Activating the Nrf2/ARE Pathway in Glomerular Mesangial Cells

Dapagliflozin restores autophagy and attenuates apoptosis via the AMPK/mTOR pathway in diabetic nephropathy rats and high glucose-induced HK-2 cells

Dendropanoxide Attenuates High Glucose-induced Oxidative Damage in NRK-52E Cells via AKT/mTOR Signaling Pathway

Fluorofenidone Inhibits Nicotinamide Adeninedinucleotide Phosphate Oxidase Via PI3K/Akt Pathway in the Pathogenesis of Renal Interstitial Fibrosis

Asiaticoside improves diabetic nephropathy by reducing inflammation, oxidative stress, and fibrosis: An in vitro and in vivo study

Ginsenoside Rg1 treatment alleviates renal fibrosis by inhibiting the NOX4–MAPK pathway in T2DM mice

Vitamin D receptor alleviates lipid peroxidation in diabetic nephropathy by regulating ACLY/Nrf2/Keap1 pathway